<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165723</url>
  </required_header>
  <id_info>
    <org_study_id>B0141007</org_study_id>
    <nct_id>NCT01165723</nct_id>
  </id_info>
  <brief_title>A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated</brief_title>
  <official_title>A Randomised, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group Study To Evaluate the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses PF-04427429 Administered Intravenously To Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of PF-04472429 administered intravenously to healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (incidence/severity of adverse events and clinical laboratory abnormalities, mean change from baseline/placebo in vital signs/body temperature, mean change from baseline in 12 lead electrocardiogram parameters compared to baseline/placebo)</measure>
    <time_frame>up to 129 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety continued (categorical summary of QTcF compared to baseline between dose groups and placebo, concentration QTcF relationship, ADA responses, IV injection site reactions</measure>
    <time_frame>up to 129 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (free plasma concentrations of PF-04427429 will be measured by a validated assay and non-compartmental PK parameters will be determined for each dose)</measure>
    <time_frame>up to 129 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamics (free and total CGRP plasma concentration) will be measured, the PK-PD relationship between plasma PF-0447429 concentrations and free/total CGRP concentrations will be characterised</measure>
    <time_frame>up to 129 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IV Dose 1: experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 2: experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04427429</intervention_name>
    <description>Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30</description>
    <arm_group_label>IV Dose 1: experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04427429</intervention_name>
    <description>Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30</description>
    <arm_group_label>IV Dose 2: experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 50 years inclusive. (healthy is
             defined as non clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory tests)

          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight of 50 to 100kg
             inclusive

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject (or a legally acceptable representative) has been informed of all
             pertinent aspects of the trial

        Exclusion Criteria:

          -  Evidence or history of clinically significant haematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic or
             allergic disease (including drug allergies, but excluding untreated symptomatic,
             seasonal allergies at time of dosing)

          -  History of febrile illness within 5 days prior to the first dose

          -  A positive urine drug screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0141007&amp;StudyName=A%20Clinical%20Study%20Evaluating%20The%20Safety%20And%20Tolerability%20Of%20PF-04427429%20In%20Healthy%20Adult%20Volunteers.%20The%20Pharmacokinetics%20And%20Pharmacodynamic</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>chronic pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

